Patent classifications
A61K36/185
HOMEOPATHIC METHOD FOR TREATING COLIC, GAS AND UPSET STOMACH IN INFANTS
The present invention generally relates to homeopathic compositions, and, more particularly, (i) homeopathic compositions comprising a homeopathically potentised form of Passiflora incarnata (Passionflower), and a homeopathically potentised form of Nux Moschata (Nutmeg); or (ii) a homeopathically potentised Carbo Vegetabilis; and a homeopathically potentised Passiflora incarnata; or (iii) a homeopathically potentised Carbo Vegetabilis; and a homeopathically potentised Nux Moschata; and methods of treatment using these homeopathic compositions.
HOMEOPATHIC METHOD FOR TREATING COLIC, GAS AND UPSET STOMACH IN INFANTS
The present invention generally relates to homeopathic compositions, and, more particularly, (i) homeopathic compositions comprising a homeopathically potentised form of Passiflora incarnata (Passionflower), and a homeopathically potentised form of Nux Moschata (Nutmeg); or (ii) a homeopathically potentised Carbo Vegetabilis; and a homeopathically potentised Passiflora incarnata; or (iii) a homeopathically potentised Carbo Vegetabilis; and a homeopathically potentised Nux Moschata; and methods of treatment using these homeopathic compositions.
COMPOSITION AND METHODS TO IMPROVE STABILITY, DOSING, PHARMACODYNAMICS AND PRODUCT SHELF LIFE OF ENDOCANNABINOIDS, PHYTOCANNABINOIDS AND SYNTHETIC CANNABINOIDS DELIVERED BY NASAL INHAER
An inhaler-delivery-device-packaged homogenate of solid heterogeneous-lipid particulates carrying lipophilic cannabinoid receptor agonists and/or antagonists, wherein the solid heterogeneous-lipid particles comprises: one (or more) lipid(s) whose melting point(s) is (are) substantially above room temperature; in combination with, one (or more) lipid(s) whose melting point(s) is (are) substantially less than room temperature.
Low-Temperature Inhalation Administration of Cannabinoid Entities
A cannabinoid material as active agent containing formulation comprising the active agent, an HFA propellant, and optionally a co-solvent is disclosed. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 50° C.
Smoking device
Apparatus and methods are described for use with a portion of plant material that includes at least one active ingredient. A vaporizing unit includes a heating element configured to heat the plant material, and a sensor configured to detect an indication of airflow rate through the vaporizing unit. Control circuitry is configured to receive an indication of the airflow rate through the vaporizing unit, and, in response thereto, to determine a smoking profile that is desired by the user. The control circuitry drives the heating element to vaporize the active ingredient of the plant material by heating the plant material according to the determined smoking profile. The control circuitry dynamically updates the smoking profile in response to changes in airflow rate over the course of a smoking session. Other applications are also described.
Smoking device
Apparatus and methods are described for use with a portion of plant material that includes at least one active ingredient. A vaporizing unit includes a heating element configured to heat the plant material, and a sensor configured to detect an indication of airflow rate through the vaporizing unit. Control circuitry is configured to receive an indication of the airflow rate through the vaporizing unit, and, in response thereto, to determine a smoking profile that is desired by the user. The control circuitry drives the heating element to vaporize the active ingredient of the plant material by heating the plant material according to the determined smoking profile. The control circuitry dynamically updates the smoking profile in response to changes in airflow rate over the course of a smoking session. Other applications are also described.
PROCESS FOR PURIFYING GLANDULAR TRICHOMES
The present invention relates to a dry process for isolating clean glandular trichomes from a trichome bearing plant material, wherein the trichome bearing plant material is frozen at −20° C. and subject to shattering and softening sequence.
Horizontal Axis Rotary Separation Apparatus and Process
A horizontal axis rotary separation apparatus is deployed in a process for separating resinous trichomes rich in flavoring, aromatic and/or medicinal components produced in plant trichome glands from unwanted plant matter. The process physically separates resin rich beads at the trichome gland head from extraneous plant matter by one or move separation sieves. The sieves are provided in or as a casing over a rigid frame member. The sieves are mesh fabric bags or screen that are easily opened and replenished in a batch operating mode, and are removable from the frame for cleaning and maintenance. Other aspects of the invention include processes that improve process efficiency and speed, and yield products of superior quality.
Horizontal Axis Rotary Separation Apparatus and Process
A horizontal axis rotary separation apparatus is deployed in a process for separating resinous trichomes rich in flavoring, aromatic and/or medicinal components produced in plant trichome glands from unwanted plant matter. The process physically separates resin rich beads at the trichome gland head from extraneous plant matter by one or move separation sieves. The sieves are provided in or as a casing over a rigid frame member. The sieves are mesh fabric bags or screen that are easily opened and replenished in a batch operating mode, and are removable from the frame for cleaning and maintenance. Other aspects of the invention include processes that improve process efficiency and speed, and yield products of superior quality.
USE OF EMBLICA EXTRACT IN PREPARING PHARMACEUTICAL COMPOSITION FOR PROTECTING MITOCHONDRIA IN RETINA
A use of an emblica extract in preparing a pharmaceutical composition for protecting mitochondria in retina is provided. When the pharmaceutical composition, which comprises the emblica extract, is provided to retinal cells, a use of the pharmaceutical composition comprises improvement of the ability of performing the oxidative phosphorylation for the synthesis of the adenosine triphosphate (ATP) by the mitochondria in the retinal cells under or exposed to ultraviolet light, and improvement of the coupling efficiency of the synthesis of the adenosine triphosphate by the mitochondria.